Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee

Completed · Phase 3

Conditions studied: Osteoarthritis

In brief

An open-label, single-arm clinical trial to confirm the safety of monoarticular injections or bi-lateral intra-articular injections of RTX-GRT7039 in patients who have pain associated with osteoarthritis of the knee despite standard of care.

Key facts

Study ID

NCT05377489

Run by

Grünenthal GmbH

People needed

714

Starts

2022-09-15

Expected to finish

2025-05-15

Last updated by the study team

2026-03-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The participant has given written informed consent to participate.
• The participant is 18 years of age or older at the Screening Visit.
• The participant has a diagnosis of osteoarthritis of the knee based on American College of Rheumatology criteria and functional capacity class of I to III.
• There is a documented history indicating that participant has insufficient pain relief with previous Standard of Care.

You may not qualify if…

• The participant has past joint replacement surgery of the index knee.
• The participant has a history of significant trauma or surgery (e.g., open or arthroscopic) to the index knee within 12 months of Screening.
• The participant has periarticular pain at the index knee from any cause other than osteoarthritis, including referred pain, bursitis, tendonitis.
• The participant has clinical hip osteoarthritis on the side of the index knee.
• The participant has a history of osteonecrosis, subchondral insufficiency fracture, atrophic osteoarthritis, rapidly progressing osteoarthritis (RPOA) Type I or Type II,pathologic fracture, primary or metastatic tumor, or joint infection in the index knee.
• The participant has significant malalignment of anatomical axis (medial angle formed by the femur and tibia) of the target knee (varus >10°, valgus >10°) by radiograph as assessed by independent Central Readers at Screening Visit.
• The participant has other conditions that could affect trial endpoint assessments of the index knee.
• The participant has current clinically significant disease(s) or condition(s) that may affect safety assessments, or any other reason which may preclude the participant's participation for the full duration of the trial.
• The participant has a history of hypersensitivity to resiniferatoxin (RTX) or any similar component (capsaicin, chili peppers).
• The participant is currently participating or was participating in another investigational drug trial within 3 months prior to the Screening Visit.
• The participant is an employee of the investigator or trial site, with direct involvement in the proposed trial or other trials under the direction of that investigator or trial site or is a family member of the employees or the investigator.
• The non-index knee is not eligible for treatment in the trial, if any of the knee-related exclusion criteria applies to the non-index knee.

Where it is running

• Elite Clinical Studies, LLC — Phoenix, Arizona, United States
• Orange County Research Institute — Anaheim, California, United States
• Acclaim Clinical Research, Inc. — San Diego, California, United States
• Westlake Medical Research — Thousand Oaks, California, United States
• Progressive Medical Research — Port Orange, Florida, United States
• Gulfcoast Research Institute — Sarasota, Florida, United States
• Palm Beach Research Center — West Palm Beach, Florida, United States
• North Georgia Clinical Research — Woodstock, Georgia, United States
• Injury Care Research — Boise, Idaho, United States
• Chicago Clinical Research Institute Inc. — Chicago, Illinois, United States
• OrthoIndy, Inc. — Greenwood, Indiana, United States
• University Of Kansas Medical Center — Kansas City, Kansas, United States
• Neuroscience Research Center, LLC — Overland Park, Kansas, United States
• Clinical Pharmacology Study Group — Worcester, Massachusetts, United States
• Oakland Medical Research Center — Troy, Michigan, United States
• Excel Clinical Research — Las Vegas, Nevada, United States
• Las Vegas Clinical Trials, LLC — North Las Vegas, Nevada, United States
• Drug Trials America — Hartsdale, New York, United States
• M3-Emerging Medical Research, LLC — Durham, North Carolina, United States
• M3-Emerging Medical Research, LLC — Raleigh, North Carolina, United States
• University Orthopedics Center — State College, Pennsylvania, United States
• Coastal Carolina Research Center — Mt. Pleasant, South Carolina, United States
• Coastal Carolina Research Center — North Charleston, South Carolina, United States
• Accellacare-Knoxville — Knoxville, Tennessee, United States
• Arizona Arthritis and Rheumatology Associates (AARA) P.C — Glendale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.